TROP2 is associated with the recurrence of patients with non-muscle invasive bladder cancer

International Journal of Clinical and Experimental Medicine

Volumn 10, Issue 1, 2017, Pages 1643-1650

  Zhang, Lianhua ^a   Yang, Guoliang ^a   Jiang, Haifeng ^a   Liu, Mengyao ^a   Chen, Haige ^a   Huang, Yiran ^a   Wang, Zhiwei ^b   Bo, Juanjie ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Biomarker; Bladder cancer; Prognosis; Recurrence; TROP2

Indexed keywords

PEPTIDES AND PROTEINS; TROPHOBLASTIC CELL SURFACE ANTIGEN 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NON MUSCLE INVASIVE BLADDER CANCER; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TUMOR VOLUME;

EID: 85009387006     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Lee JY, Joo HJ, Cho DS, Kim SI, Ahn HS and Kim SJ. Prognostic Significance of Substaging according to the Depth of Lamina Propria Invasion in Primary T1 Transitional Cell Carcinoma of the Bladder. Korean J Urol 2012; 53: 317-323.
3. Youssef RF and Lotan Y. Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer. ScientificWorldJournal 2011; 11: 369-381.
4. Van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, Witjes JA and Zlotta AR. Recurrence and progression of disease in nonmuscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009; 56: 430-442.
5. Hall MC, Chang SS, Dalbagni G, Pruthi RS, Seigne JD, Skinner EC, Wolf JS Jr and Schellhammer PF. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178: 2314-2330.
6. Kamat AM, Sylvester RJ, Bohle A, Palou J, Lamm DL, Brausi M, Soloway M, Persad R, Buckley R, Colombel M and Witjes JA. Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. J Clin Oncol 2016; 34: 1935-44.
7. Bol MG, Baak JP, Buhr-Wildhagen S, Kruse AJ, Kjellevold KH, Janssen EA, Mestad O and Ogreid P. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder. J Urol 2003; 169: 1291-1294.
8. Litvinov SV, Balzar M, Winter MJ, Bakker HA, Briaire-de Bruijn IH, Prins F, Fleuren GJ and Warnaar SO. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 1997; 139: 1337-1348.
9. Balzar M, Briaire-de Bruijn IH, Rees-Bakker HA, Prins FA, Helfrich W, de Leij L, Riethmuller G, Alberti S, Warnaar SO, Fleuren GJ and Litvinov SV. Epidermal growth factor-like repeats mediate lateral and reciprocal interactions of EpCAM molecules in homophilic adhesions. Mol Cell Biol 2001; 21: 2570-2580.
10. McDougall AR, Tolcos M, Hooper SB, Cole TJ and Wallace MJ. Trop2: from development to disease. Dev Dyn 2015; 244: 99-109.
11. Cubas R, Li M, Chen C and Yao Q. Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta 2009; 1796: 309-314.
12. Ripani E, Sacchetti A, Corda D and Alberti S. Human Trop-2 is a tumor-associated calcium signal transducer. Int J Cancer 1998; 76: 671-676.
13. Shvartsur A and Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer 2015; 6: 84-105.
14. Bignotti E, Todeschini P, Calza S, Falchetti M, Ravanini M, Tassi RA, Ravaggi A, Bandiera E, Romani C, Zanotti L, Tognon G, Odicino FE, Facchetti F, Pecorelli S and Santin AD. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer 2011; 46: 944-953.
15. Cubas R, Zhang S, Li M, Chen C and Yao Q. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer 2010; 9: 253.
16. Stepan LP, Trueblood ES, Hale K, Babcook J, Borges L and Sutherland CL. Expression of Trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochem 2011; 59: 701-710.
17. Chen X, Pang B, Liang Y, Xu SC, Xin T, Fan HT, Yu YB and Pang Q. Overexpression of EpCAM and Trop2 in pituitary adenomas. Int J Clin Exp Pathol 2014; 7: 7907-7914.
18. Fong D, Spizzo G, Gostner JM, Gastl G, Moser P, Krammel C, Gerhard S, Rasse M and Laimer K. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Patho 2008; 21: 186-191.
19. Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, Gastl G and Spizzo G. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer 2008; 99: 1290-1295.
20. Zhao W, Zhu H, Zhang S, Yong H, Wang W, Zhou Y, Wang B, Wen J, Qiu Z, Ding G, Feng Z and Zhu J. Trop2 is overexpressed in gastric cancer and predicts poor prognosis. Oncotarget 2016; 7: 6136-45.
21. Chen MB, Wu HF, Zhan Y, Fu XL, Wang AK, Wang LS and Lei HM. Prognostic value of TROP2 expression in patients with gallbladder cancer. Tumour Biol 2014; 35: 11565-11569.
22. Cubas R, Li M, Chen C and Yao Q. Trop2: a possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta 2009; 1796: 309-314.
23. Liu T, Liu Y, Bao X, Tian J and Yang X. Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway. PLoS One 2013; 8: e75864.
24. Wang J, Day R, Dong Y, Weintraub SJ and Michel L. Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther 2008; 7: 280-285.
25. Ning S, Liang N, Liu B, Chen X, Pang Q and Xin T. TROP2 expression and its correlation with tumor proliferation and angiogenesis in human gliomas. Neurol Sci 2013; 34: 1745-1750.
26. Muhlmann G, Spizzo G, Gostner J, Zitt M, Maier H, Moser P, Gastl G, Muller HM, Margreiter R, Ofner D and Fong D. TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol 2009; 62: 152-158.
27. Kapoor S. TROP2 expression and its evolving role in tumor pathogenesis in systemic tumors. Tumour Biol 2013; 34: 1967-1968.
28. Guan GF, Zhang DJ, Wen LJ, Yu DJ, Zhao Y, Zhu L, Guo YY and Zheng Y. Prognostic value of TROP2 in human nasopharyngeal carcinoma. Int J Clin Exp Pathol 2015; 8: 10995-11004.
29. Fong D, Spizzo G, Gostner JM, Gastl G, Moser P, Krammel C, Gerhard S, Rasse M and Laimer K. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol 2008; 21: 186-191.
30. Gao XY, Zhu YH, Zhang LX, Lu HY and Jiang AG. siRNA targeting of Trop2 suppresses the proliferation and invasion of lung adenocarcinoma H460 cells. Exp Ther Med 2015; 10: 429-434.
31. Li Z, Jiang X and Zhang W. TROP2 overexpression promotes proliferation and invasion of lung adenocarcinoma cells. Biochem Biophys Res Commun 2016; 470: 197-204.
32. Stoyanova T, Goldstein AS, Cai H, Drake JM, Huang J and Witte ON. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via beta-catenin signaling. Genes Dev 2012; 26: 2271-2285.
33. Trerotola M, Cantanelli P, Guerra E, Tripaldi R, Aloisi AL, Bonasera V, Lattanzio R, de Lange R, Weidle UH, Piantelli M and Alberti S. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene 2013; 32: 222-233.
34. Sawanyawisuth K, Tantapotinan N, Wongkham C, Riggins GJ, Kraiklang R, Wongkham S and Puapairoj A. Suppression of trophoblast cell surface antigen 2 enhances proliferation and migration in liver fluke-associated cholangiocarcinoma. Ann Hepatol 2015; 15: 71-81.
35. Zhang K, Jones L, Lim S, Maher CA, Adkins D, Lewis J, Kimple RJ, Fertig EJ, Chung CH, Van Tine BA, Ellis MJ, Herrlich A and Michel LS. Loss of Trop2 causes ErbB3 activation through a neuregulin-1-dependent mechanism in the mesenchymal subtype of HNSCC. Oncotarget 2014; 5: 9281-9294.
36. Liu X, Li S and Yi F. Trop2 gene: a novel target for cervical cancer treatment. J Cancer Res Clin Oncol 2014; 140: 1331-1341.
37. Liu T, Tian J, Chen Z, Liang Y, Liu J, Liu S, Li H, Zhan J and Yang X. Anti-TROP2 conjugated hollow gold nanospheres as a novel nanostructure for targeted photothermal destruction of cervical cancer cells. Nanotechnology 2014; 25: 345103.
38. Lin H, Zhang H, Wang J, Lu M, Zheng F, Wang C, Tang X, Xu N, Chen R, Zhang D, Zhao P, Zhu J, Mao Y and Feng Z. A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo. Int J Cancer 2014; 134: 1239-1249.